Clinical trials: Overactive Detrusor
Detrusor Underactivity, Overactive Bladder
Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
The purpose of this study is to evaluate the efficacy and safety of TAC-302 in detrusor underactivity patients with overactive bladder.
- Trial name
- NCT03175029
- Testing
- TAC-302
- Where
- Japan
- Volunteers
- 195 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Detrusor Overactivity, Overactive Bladder
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.
- Trial name
- SHRINK (NCT01093534)
- Testing
- solifenacin
- Where
- 79 sites in United States, Austria and 18 more
- Volunteers
- 547 people
- Sponsor
- Astellas Pharma Inc
Overactive Detrusor, Neurogenic Bladder
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition.
- Trial name
- NCT01192568
- Testing
- Oxybutynin
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- AbbVie
Detrusor Overactivity, Multiple Sclerosis
A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis
The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in reducing the daily number of episodes on incontinence.
- Trial name
- NCT00678795
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 135 people
- Sponsor
- Jazz Pharmaceuticals
Neurogenic Detrusor Overactivity
A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity
This study will evaluate the pharmacodynamics and pharmacokinetics of darifenacin liquid oral suspension in children, ages 2-15 years, with neurogenic detrusor overactivity.
- Trial name
- NCT00712322
- Testing
- Darifenacin
- Where
- 12 sites in United States, Colombia
- Volunteers
- 35 people
- Sponsor
- Warner Chilcott
Neurogenic Overactive Bladder, Urinary Incontinence
Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
The study is designed to demonstrate that treatment with low level stimulation of the bladder muscles reduces symptoms of urinary incontinence in comparison with no stimulation.
- Conditions
- Neurogenic Overactive Bladder, Urinary Incontinence, Detrusor Overactivity
- Trial name
- ACCEPTANCE (NCT01023269)
- Testing
- InterStim Therapy
- Where
- 8 sites in Belgium, France and 4 more
- Volunteers
- 17 people
- Sponsor
- MedtronicNeuro
Overactive Bladder, Detrusor Overactivity
A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function
The purpose of this study is to assess if the study drug, Vardenafil (approved by Health Authorities is available on the market for treatment of erectile dysfunction) has an effect on bladder function and micturition frequency.
- Trial name
- NCT00478881
- Testing
- Vardenafil HCl (Levitra, BAY38-9456)
- Where
- 55 sites in Belgium, Canada and 11 more
- Volunteers
- 397 people
- Sponsor
- Bayer
Detrusor Function, Overactive
Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity
The purpose of this study is to evaluate the effects and tolerability (how well a participant can stand a particular medicine or treatment) of flexible dose Oxybutynin Extended-Release (OXY-ER, Lyrinel) including safety and…
- Trial name
- RONDO (NCT01796548)
- Testing
- Oxybutinin Extended-Release
- Where
- 3 sites in Thailand
- Volunteers
- 17 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Overactive Bladder, Neurogenic Detrusor Overactivity
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.
- Trial name
- NCT00857896
- Testing
- Fesoterodine
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pfizer